Biomarkers and personalized medicine in heart failure

Jasper Tromp

Biomarkers and personalized medicine in heart failure

Onderzoeksoutput

753 Downloads (Pure)

Samenvatting

Treating heart failure is one of the greatest unmet needs in cardiovascular medicine today. Overall survival is poor and 50% of patients die within 5 years of their initial diagnosis. Heart failure is a heterogeneous syndrome and a one-size-fits-all approach is ineffective. Therefore, in my thesis I used biomarkers to 1. Show that patients with heart failure and a preserved ejection fraction are subject to more inflammation, which can be a key treatment target and 2. Identified clinical relevant subgroups with differences in response to treatment using machine learning based approaches.

Originele taal-2	English
Kwalificatie	Doctor of Philosophy
Toekennende instantie	Rijksuniversiteit Groningen
Begeleider(s)/adviseur	van der Meer, Peter, Supervisor Voors, Adriaan, Supervisor Brunner-La Rocca, Hans-Peter, Beoordelingscommissie, Externe Persoon van Gilst, Wiek, Beoordelingscommissie
Datum van toekenning	17-sep-2018
Plaats van publicatie	[Groningen]
Uitgever	Rijksuniversiteit Groningen
Gedrukte ISBN's	978-94-034-1064-7
Elektronische ISBN's	978-94-034-1063-0
Status	Published - 2018

Toegang tot document

Title and contentsFinal publisher's version, 1,58 MB
Chapter 1Final publisher's version, 2,33 MB
Chapter 2Final publisher's version, 1,66 MB
Chapter 3Final publisher's version, 2,78 MB
Chapter 4Final publisher's version, 5,43 MB
Chapter 5Final publisher's version, 2,9 MB
Chapter 6Final publisher's version, 2,4 MB
Chapter 7Final publisher's version, 1,88 MB
Chapter 8Final publisher's version, 1,57 MB
AppendicesFinal publisher's version, 729 KB
Complete thesisFinal publisher's version, 10,3 MB
PropositionsFinal publisher's version, 137 KB

Citeer dit

@phdthesis{bb92335eb52b4d708ca64bf621225586,

title = "Biomarkers and personalized medicine in heart failure",

abstract = "Treating heart failure is one of the greatest unmet needs in cardiovascular medicine today. Overall survival is poor and 50% of patients die within 5 years of their initial diagnosis. Heart failure is a heterogeneous syndrome and a one-size-fits-all approach is ineffective. Therefore, in my thesis I used biomarkers to 1. Show that patients with heart failure and a preserved ejection fraction are subject to more inflammation, which can be a key treatment target and 2. Identified clinical relevant subgroups with differences in response to treatment using machine learning based approaches.",

author = "Jasper Tromp",

year = "2018",

language = "English",

isbn = "978-94-034-1064-7",

publisher = "Rijksuniversiteit Groningen",

school = "University of Groningen",

}

TY - THES

T1 - Biomarkers and personalized medicine in heart failure

AU - Tromp, Jasper

PY - 2018

Y1 - 2018

N2 - Treating heart failure is one of the greatest unmet needs in cardiovascular medicine today. Overall survival is poor and 50% of patients die within 5 years of their initial diagnosis. Heart failure is a heterogeneous syndrome and a one-size-fits-all approach is ineffective. Therefore, in my thesis I used biomarkers to 1. Show that patients with heart failure and a preserved ejection fraction are subject to more inflammation, which can be a key treatment target and 2. Identified clinical relevant subgroups with differences in response to treatment using machine learning based approaches.

AB - Treating heart failure is one of the greatest unmet needs in cardiovascular medicine today. Overall survival is poor and 50% of patients die within 5 years of their initial diagnosis. Heart failure is a heterogeneous syndrome and a one-size-fits-all approach is ineffective. Therefore, in my thesis I used biomarkers to 1. Show that patients with heart failure and a preserved ejection fraction are subject to more inflammation, which can be a key treatment target and 2. Identified clinical relevant subgroups with differences in response to treatment using machine learning based approaches.

M3 - Thesis fully internal (DIV)

SN - 978-94-034-1064-7

PB - Rijksuniversiteit Groningen

CY - [Groningen]

ER -